New drug shows promise for relieving severe itch in liver disease

NCT ID NCT04167358

Ongoing Symptom relief Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the long-term safety of linerixibat, a drug for severe itching caused by primary biliary cholangitis (PBC). All 242 participants receive the drug openly. The goal is to see if it remains safe over time and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: linerixibat
What this could lead to: If successful, this could confirm linerixibat as a safe long-term option to ease severe itching in people with primary biliary cholangitis.
What could go wrong: This is an open-label study with no placebo group, so results may be biased. It focuses on safety, not whether the drug works better than no treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholestasis primary biliary cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHOLESTASIS

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Davis, California, 95817, United States
GSK Investigational Site

West Hollywood, California, 90048, United States
GSK Investigational Site

Miami, Florida, 33136, United States
GSK Investigational Site

Detroit, Michigan, 48377, United States
GSK Investigational Site

New York, New York, 10016, United States
GSK Investigational Site

Durham, North Carolina, 27710, United States
GSK Investigational Site

Morrisville, North Carolina, 27560, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19104, United States
GSK Investigational Site

Dallas, Texas, 75390, United States
GSK Investigational Site

Houston, Texas, 77030, United States
GSK Investigational Site

Seattle, Washington, 98105, United States
GSK Investigational Site

Buenos Aires, C1061AAS, Argentina
GSK Investigational Site

Capital Federal, C1181ACI, Argentina
GSK Investigational Site

Ciudad AutOnoma de Buenos Aire, 1118, Argentina
GSK Investigational Site

Ciudad Autonoma de Bueno, C1056ABI, Argentina
GSK Investigational Site

Rosario, S2002KDT, Argentina
GSK Investigational Site

Santa Fe, 3000, Argentina
GSK Investigational Site

Porto Alegre, Rio Grande do Sul, 90035003, Brazil
GSK Investigational Site

Botucatu, 18618686, Brazil
GSK Investigational Site

Brasília, 70335-900, Brazil
GSK Investigational Site

Salvador, 40110-160, Brazil
GSK Investigational Site

Sofia, 1618, Bulgaria
GSK Investigational Site

Edmonton, Alberta, T6G 2X8, Canada
GSK Investigational Site

Toronto, Ontario, M5G 2C4, Canada
GSK Investigational Site

Beijing, 100032, China
GSK Investigational Site

Beijing, 100069, China
GSK Investigational Site

Changchun, 130021, China
GSK Investigational Site

Chongqing, 400042, China
GSK Investigational Site

Guangzhou, 510630, China
GSK Investigational Site

Nanchang, 330006, China
GSK Investigational Site

Nanjing, 210003, China
GSK Investigational Site

Shanghai, 200127, China
GSK Investigational Site

Tianjin, 300000, China
GSK Investigational Site

Pilsen, 30100, Czechia
GSK Investigational Site

Prague, 140 21, Czechia
GSK Investigational Site

Lille, 59037, France
GSK Investigational Site

Erlangen, 91054, Germany
GSK Investigational Site

Münster, 48149, Germany
GSK Investigational Site

Haifa, 34362, Israel
GSK Investigational Site

Holon, 58100, Israel
GSK Investigational Site

Jerusalem, 91120, Israel
GSK Investigational Site

Rehovot, 76100, Israel
GSK Investigational Site

Milan, 20142, Italy
GSK Investigational Site

Modena, 41126, Italy
GSK Investigational Site

Monza, 20900, Italy
GSK Investigational Site

Naples, 80131, Italy
GSK Investigational Site

Negrar Verona, 37024, Italy
GSK Investigational Site

Padova, 35128, Italy
GSK Investigational Site

Palermo, 90127, Italy
GSK Investigational Site

Roma, 00168, Italy
GSK Investigational Site

Chiba, 270-1694, Japan
GSK Investigational Site

Ehime, 791-0295, Japan
GSK Investigational Site

Fukui, 918-8503, Japan
GSK Investigational Site

Gunma, 371-8511, Japan
GSK Investigational Site

Hiroshima, 730-8619, Japan
GSK Investigational Site

Hiroshima, 734-8551, Japan
GSK Investigational Site

Hokkaido, 006-8555, Japan
GSK Investigational Site

Kagawa, 760-8557, Japan
GSK Investigational Site

Kanagawa, 259-1143, Japan
GSK Investigational Site

Nagano, 390-8621, Japan
GSK Investigational Site

Nagasaki, 856-8562, Japan
GSK Investigational Site

Nara, 634-8522, Japan
GSK Investigational Site

Osaka, 545-8586, Japan
GSK Investigational Site

Osaka, 591-8025, Japan
GSK Investigational Site

Shizuoka, 431-3192, Japan
GSK Investigational Site

Tokyo, 113-8603, Japan
GSK Investigational Site

Tokyo, 162-8655, Japan
GSK Investigational Site

Tokyo, 173-8606, Japan
GSK Investigational Site

Tokyo, 181-8611, Japan
GSK Investigational Site

Mexico City, 06700, Mexico
GSK Investigational Site

Mexico City, 14080, Mexico
GSK Investigational Site

Monterrey, 64020, Mexico
GSK Investigational Site

Częstochowa, 42-217, Poland
GSK Investigational Site

Katowice, 40-659, Poland
GSK Investigational Site

Mysłowice, 41-400, Poland
GSK Investigational Site

Warsaw, 03-712, Poland
GSK Investigational Site

Wroclaw, 51-162, Poland
GSK Investigational Site

Kemerovo, 650000, Russia
GSK Investigational Site

Moscow, 119121, Russia
GSK Investigational Site

Samara, 443063, Russia
GSK Investigational Site

Barcelona, 08036, Spain
GSK Investigational Site

Madrid, 28007, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Seville, 41013, Spain
GSK Investigational Site

Valencia, 46026, Spain
GSK Investigational Site

Basingstoke, RG24 9NA, United Kingdom
GSK Investigational Site

Glasgow, G31 2ER, United Kingdom
GSK Investigational Site

London, NW3 2QG, United Kingdom
GSK Investigational Site

Newcastle upon Tyne, NE4 5PL, United Kingdom
GSK Investigational Site

Nottingham, NG7 2UH, United Kingdom
GSK Investigational Site

Plymouth, PL6 8DH, United Kingdom
GSK Investigational Site

Reading Berkshire, RG1 5AN, United Kingdom
GSK Investigational Site

Southampton, SO16 6YD, United Kingdom
GSK Investigational Site

Surrey, RH1 5RH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.